Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.
Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.
Published on
In 2014 Gilead Pharma launched the first oral HCV medication, Sovaldi. Soon after launch, the drug became a blockbuster hit in Pharma industry. Sovaldi’s high cure rate, short dosage period, less severe side effects, large target market and increased demand helped drive $2.3 billion sales in the first quarter itself.
This case study showcases the strategy and tactics utilized by Gilead in achieving blockbuster status for Sovaldi. It also highlights a nine step analysis of strategy/tactics essential for new product launch.
Download the full Report: http://bit.ly/1PLJqND
Login to see the comments